Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30582718 | 0.89 | KMT2A (0.53) | HRH1CCR3KCNH2KMT2AMEN1 | |
| SCHEMBL13654228 | 0.89 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPTCHRM4 | |
| SCHEMBL4038173 | 0.88 | KMT2A (0.49) | KMT2AMEN1ALDH1A1MAPTCHRM4 | |
| SCHEMBL5213714 | 0.87 | HRH1 (0.52) | HRH1CCR3KCNH2SIGMAR1KMT2A | |
| SCHEMBL4032439 | 0.85 | KMT2A (0.47) | SIGMAR1KMT2ADRD2MEN1ALDH1A1 | |
| SCHEMBL4034760 | 0.85 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPTCHRM4 | |
| SCHEMBL4032437 | 0.81 | KMT2A (0.48) | KMT2AMEN1ALDH1A1MAPTCHRM4 | |
| SCHEMBL4032905 | 0.80 | KMT2A (0.57) | HRH1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4781640 | 0.78 | MAPT (0.57) | KMT2AMEN1ALDH1A1MAPTGPR119 | |
| SCHEMBL4667171 | 0.78 | MAPT (0.57) | KMT2AMEN1ALDH1A1MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | HRH1 658/4885CCR3 4514/4885KCNH2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.